These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30227653)

  • 1. Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines.
    Simiczyjew A; Dratkiewicz E; Van Troys M; Ampe C; Styczeń I; Nowak D
    Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30227653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells' Invasive Abilities.
    Simiczyjew A; Pietraszek-Gremplewicz K; Dratkiewicz E; Podgórska M; Matkowski R; Ziętek M; Nowak D
    Front Pharmacol; 2019; 10():1116. PubMed ID: 31649529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines.
    Dratkiewicz E; Pietraszek-Gremplewicz K; Simiczyjew A; Mazur AJ; Nowak D
    Oncotarget; 2018 Apr; 9(26):18254-18268. PubMed ID: 29719603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.
    Sohn J; Liu S; Parinyanitikul N; Lee J; Hortobagyi GN; Mills GB; Ueno NT; Gonzalez-Angulo AM
    J Cancer; 2014; 5(9):745-53. PubMed ID: 25368674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
    Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
    Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
    Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
    Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
    Cancer Metab; 2017; 5():6. PubMed ID: 28852500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.
    Goltsov AA; Fang B; Pandita TK; Maru DM; Swisher SG; Hofstetter WL
    Ann Thorac Surg; 2018 Feb; 105(2):363-370. PubMed ID: 29223420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
    Yi YW; You K; Bae EJ; Kwak SJ; Seong YS; Bae I
    Int J Oncol; 2015 Jul; 47(1):122-32. PubMed ID: 25955731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
    Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
    Rayson D; Lupichuk S; Potvin K; Dent S; Shenkier T; Dhesy-Thind S; Ellard SL; Prady C; Salim M; Farmer P; Allo G; Tsao MS; Allan A; Ludkovski O; Bonomi M; Tu D; Hagerman L; Goodwin R; Eisenhauer E; Bradbury P
    Breast Cancer Res Treat; 2016 May; 157(1):109-16. PubMed ID: 27116183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG
    Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
    Nakai K; Hung MC; Yamaguchi H
    Am J Cancer Res; 2016; 6(8):1609-23. PubMed ID: 27648353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
    Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
    Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.
    Hsia TC; Tu CY; Chen YJ; Wei YL; Yu MC; Hsu SC; Tsai SL; Chen WS; Yeh MH; Yen CJ; Yu YL; Huang TC; Huang CY; Hung MC; Huang WC
    Mol Pharmacol; 2013 Apr; 83(4):857-69. PubMed ID: 23355539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
    Corkery B; Crown J; Clynes M; O'Donovan N
    Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.